{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T00:05:50Z","timestamp":1788998750567,"version":"build-2803163510"},"reference-count":12,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,5,7]]},"DOI":"10.7759\/cureus.24804","type":"journal-article","created":{"date-parts":[[2022,5,7]],"date-time":"2022-05-07T15:28:47Z","timestamp":1651937327000},"source":"Crossref","is-referenced-by-count":6,"title":["A Case of Bullous Pemphigoid Associated With Nivolumab Therapy"],"prefix":"10.7759","author":[{"given":"Nico","family":"Gotera","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pablo","family":"Weilg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caio","family":"Heleno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalia","family":"Ferrari-Gabilondo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","article-title":"Nivolumab","author":"Rendon A","year":"2021","unstructured":"Rendon A, Rayi A. Nivolumab. StatPearls. StatPearls Publishing, Treasure Island, Florida; 2021."},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2018-0128","article-title":"A case of nivolumab-induced bullous pemphigoid: review of dermatologic toxicity associated with programmed cell death protein-1\/programmed death ligand-1 inhibitors and recommendations for diagnosis and management","volume":"23","author":"Lopez AT","year":"2018","unstructured":"Lopez AT, Geskin L. A case of nivolumab-induced bullous pemphigoid: review of dermatologic toxicity associated with programmed cell death protein-1\/programmed death ligand-1 inhibitors and recommendations for diagnosis and management. Oncologist. 2018, 23:1119-26. 10.1634\/theoncologist.2018-0128","journal-title":"Oncologist"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1111\/ijd.13984","article-title":"A review of bullous pemphigoid associated with PD-1 and PD-L1 inhibitors","volume":"57","author":"Lopez AT","year":"2018","unstructured":"Lopez AT, Khanna T, Antonov N, Audrey-Bayan C, Geskin L. A review of bullous pemphigoid associated with PD-1 and PD-L1 inhibitors. Int J Dermatol. 2018, 57:664-9. 10.1111\/ijd.13984","journal-title":"Int J Dermatol"},{"key":"ref4","unstructured":"Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. (2021). Accessed. April 20, 2022: https:\/\/safetyprofiler-ctep.nci.nih.gov\/safety-profiler\/static\/#\/home\/(body:ctcDictionary)?version=5.0."},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2018.1912","article-title":"Timing of onset of adverse cutaneous reactions associated with programmed cell death protein 1 inhibitor therapy","volume":"154","author":"Wang LL","year":"2018","unstructured":"Wang LL, Patel G, Chiesa-Fuxench ZC, et al.. Timing of onset of adverse cutaneous reactions associated with programmed cell death protein 1 inhibitor therapy. JAMA Dermatol. 2018, 154:1057-61. 10.1001\/jamadermatol.2018.1912","journal-title":"JAMA Dermatol"},{"key":"ref6","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaad.2018.07.008","article-title":"Bullous disorders associated with anti-PD-1 and anti-PD-L1 therapy: a retrospective analysis evaluating the clinical and histopathologic features, frequency, and impact on cancer therapy","volume":"79","author":"Siegel J","year":"2018","unstructured":"Siegel J, Totonchy M, Damsky W, et al.. Bullous disorders associated with anti-PD-1 and anti-PD-L1 therapy: a retrospective analysis evaluating the clinical and histopathologic features, frequency, and impact on cancer therapy. J Am Acad Dermatol. 2018, 79:1081-8.","journal-title":"J Am Acad Dermatol"},{"key":"ref7","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaad.2020.04.105","article-title":"Dermatologic toxicities to immune checkpoint inhibitor therapy: a review of histopathologic features","volume":"83","author":"Ellis SR","year":"2020","unstructured":"Ellis SR, Vierra AT, Millsop JW, Lacouture ME, Kiuru M. Dermatologic toxicities to immune checkpoint inhibitor therapy: a review of histopathologic features. J Am Acad Dermatol. 2020, 83:1130-43.","journal-title":"J Am Acad Dermatol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.4103\/0022-3859.150906","article-title":"A case of paraneoplastic bullous pemphigoid in association with squamous cell carcinoma of lung","volume":"61","author":"Das A","year":"2015","unstructured":"Das A, Das S, Das SK, Basuthakur S. A case of paraneoplastic bullous pemphigoid in association with squamous cell carcinoma of lung. J Postgrad Med. 2015, 61:197-9. 10.4103\/0022-3859.150906","journal-title":"J Postgrad Med"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1111\/dth.13030","article-title":"Bullous pemphigoid in a patient treated with nivolumab","volume":"32","author":"Cuenca-Barrales C","year":"2019","unstructured":"Cuenca-Barrales C, Espadafor-L\u00f3pez B, Mart\u00ednez-L\u00f3pez A, Cancela-D\u00edez B, Ruiz-Villaverde R. Bullous pemphigoid in a patient treated with nivolumab. Dermatol Ther. 2019, 32:e13030. 10.1111\/dth.13030","journal-title":"Dermatol Ther"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-019-0669-y","article-title":"A prospective cohort study on the pharmacokinetics of nivolumab in metastatic non-small cell lung cancer, melanoma, and renal cell cancer patients","volume":"7","author":"Hurkmans DP","year":"2019","unstructured":"Hurkmans DP, Basak EA, van Dijk T, et al.. A prospective cohort study on the pharmacokinetics of nivolumab in metastatic non-small cell lung cancer, melanoma, and renal cell cancer patients. J Immunother Cancer. 2019, 7:192. 10.1186\/s40425-019-0669-y","journal-title":"J Immunother Cancer"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1097\/CJI.0000000000000210","article-title":"Bullous pemphigoid-like skin lesions and overt eosinophilia in a patient with melanoma treated with nivolumab: case report and review of the literature","volume":"41","author":"Anastasopoulou A","year":"2018","unstructured":"Anastasopoulou A, Papaxoinis G, Diamantopoulos P, Christofidou E, Benopoulou O, Stratigos A, Gogas H. Bullous pemphigoid-like skin lesions and overt eosinophilia in a patient with melanoma treated with nivolumab: case report and review of the literature. J Immunother. 2018, 41:164-7. 10.1097\/CJI.0000000000000210","journal-title":"J Immunother"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.5826\/dpc.1003a50","article-title":"Pemphigus vulgaris and bullous pemphigoid: update on diagnosis and treatment","volume":"10","author":"Di Lernia V","year":"2020","unstructured":"Di Lernia V, Casanova DM, Goldust M, Ricci C. Pemphigus vulgaris and bullous pemphigoid: update on diagnosis and treatment. Dermatol Pract Concept. 2020, 10:e2020050. 10.5826\/dpc.1003a50","journal-title":"Dermatol Pract Concept"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/95453-a-case-of-bullous-pemphigoid-associated-with-nivolumab-therapy","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:41:24Z","timestamp":1707507684000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/95453-a-case-of-bullous-pemphigoid-associated-with-nivolumab-therapy"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,7]]},"references-count":12,"URL":"https:\/\/doi.org\/10.7759\/cureus.24804","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2022,5,7]]}}}